

## Supplementary materials

### eMethods. Supplemental Methods

eTable 1. Raw data of clinical characteristics and laboratory results from included studies in Wuhan

eTable 2. Raw data of clinical characteristics and laboratory results from included studies outside Wuhan (including the two nationwide studies)

eFigure 1. Flow chart of studies selection

eFigure 2. Forest plot of CSR and CFR

eFigure 3. Meta-regression data for CSR and CFR using comprehensive meta-analysis software

eFigure 4. Forest plots of clinical and baseline characteristics

eFigure 5. Estimated risk of medical conditions for severity of COVID-19 (A. Mean Difference [MD] in age between severe and non-severe cases)

eFigure 6. Estimated risk of abnormal laboratory index for severity of COVID-19

eFigure 7. MD in laboratory index between severe and non-severe cases of COVID-19

eFigure 8. Forest plot showing result of sensitive analysis after excluding 1 study in turn

eFigure 9. Funnel plot

eReferences.

### eMethods Supplemental Methods

#### Definition

1. Laboratory-confirmed case

Laboratory-confirmed case was defined as the presence of SARS-CoV-2 in respiratory specimens (including nasal and pharyngeal swabs) detected by the reverse-transcriptase polymerase chain reaction (RT-PCR), which was conducted in accordance with the protocol established by the World Health Organization.<sup>1</sup> Practice of the diagnostic criteria was based on the recommendation by the National Institute for Viral Disease Control and Prevention of CDC (Available at [http://ivdc.chinacdc.cn/kyjz/202001/t20200121\\_211337.html](http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html)).

2. Severe disease

Severe disease was defined as meeting one of the following criteria: 1) presence of shortness of breath with a respiratory rate  $\geq 30$  breaths/minute; 2) an oxygen saturation ( $\text{SpO}_2$ )  $\leq 93\%$  in the resting state; 3) hypoxemia defined as an arterial partial pressure of oxygen divided by the fraction of inspired oxygen ( $\text{PaO}_2/\text{FiO}_2$  ratio)  $\leq 300$  mmHg; 4) presence of radiographic progression, defined as  $\geq 50\%$  increase of target lesion within 24–48 hours. The criterion was based on the Chinese COVID-19 prevention and control program (6th edition, <http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml>, accessed Feb 18, 2020) and American Thoracic Society guideline<sup>2</sup>.

## Search Strategies:

Search strategy for PubMed (Feb 25, 2020)

#	Searches	Results
#1	(((((virus*[Title] OR coronavirus[Title] OR nCoV[Title] OR infectious[Title] OR HCoV[Title] OR novel[Title])) AND (Wuhan[Title] OR China[Title] OR Chinese[Title] OR 2019[Title] OR 19[Title])) OR (COVID*[Title] OR SARS-CoV-2[Title] OR NCP*[Title])))	725
2#	"Coronavirus"[Mesh]	34
3#	#1 OR #2	747
4#	(clinical[Title/Abstract] OR death[Title/Abstract] OR laboratory[Title/Abstract] OR demographic*[Title/Abstract] OR baseline[Title/Abstract] OR sever*[Title/Abstract] OR outcome*[Title/Abstract] OR hospital*[Title/Abstract] OR epidemiolog*[Title/Abstract] OR ICU[Title/Abstract] OR intensive care[Title/Abstract] OR CFR[Title/Abstract] OR fatalit*[Title/Abstract] OR mortalit*[Title/Abstract])	155824
5#	#3 AND #4	331

Search strategy for Web of Science (Feb 25, 2020)

#	Searches	Results
1#	Topic: (covid-19) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	11
2#	Topic: (severe acute respiratory syndrome coronavirus 2) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	32
3#	Topic: (wuhan coronavirus) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	43
4#	Topic: (wuhan seafood market pneumonia virus) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	4
5#	Topic: (covid-19 virus) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	1
6#	Topic: (coronavirus disease 2019 virus) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	26
7#	Topic: (sars-cov-2) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	4
8#	Topic: (sars2) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	1

9#	Topic: (2019-ncov) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	61
10#	Topic: (2019 novel coronavirus) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	54
11#	#10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=2019-2020	132

Search strategy for Cochrane (Feb 25, 2020)

#	Search	Results
1#	MeSH descriptor: [Coronavirus] explode all trees	11
2#	(COVID OR coronavirus OR NCP* OR nCoV OR SARS-CoA OR HCoV OR virus*):ti,ab,kw AND (clinical AND Wuhan) (Word variations have been searched)	46
3#	#1 OR #2 Year first published Custom range 2019 to 2020	8

Search strategy for Embase (Feb 25, 2020)

#	Searches	Results
1#	'severe acute respiratory syndrome coronavirus 2'	3
2#	'wuhan coronavirus'	4
3#	'wuhan seafood market pneumonia virus'	0
4#	'covid19 virus'	0
5#	'covid-19 virus'	0
6#	'coronavirus disease 2019 virus'	0
7#	'sars-cov-2'	9
8#	'sars2'	14
9#	'2019-ncov'	99
10#	'2019 novel coronavirus'/exp OR '2019 novel coronavirus'	76
11#	(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10) AND [2019-2020]/py	132

Search strategy for Medrxiv (Feb 25, 2020)

#	Searches	Results
1#	for abstract or title "coronavirus OR COVID OR NCP* OR nCoV OR Wuhan virus" (match any words) and full text or abstract or title "clinical OR Wuhan OR 2019" (match whole any)	236

## **Quality assessment**

### **Quality Assessment Forms recommended by Agency for Healthcare Research and Quality (AHRQ) for cross-sectional study**

- 1) Define the source of information (survey, record review)
- 2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications
- 3) Indicate time period used for identifying patients
- 4) Indicate whether or not subjects were consecutive if not population-based
- 5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants
- 6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)
- 7) Explain any patient exclusions from analysis
- 8) Describe how confounding was assessed and/or controlled.
- 9) If applicable, explain how missing data were handled in the analysis
- 10) Summarize patient response rates and completeness of data collection
- 11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained

The methodological quality of the studies included was assessed using an 11-item checklist which was recommended by Agency for Healthcare Research and Quality (AHRQ). An item would be scored '0' if it was answered 'NO' or 'UNCLEAR'; if it was answered 'YES', then the item scored '1'. Article quality was assessed as follows: low quality = 0-3; moderate quality = 4-7; high quality = 8-11.

**eTable 1. Raw data of clinical characteristics and laboratory results from included studies in Wuhan.**

Study/year	Chaolin Huang et al.	Nanshan Chen et al.	Qun Li et al.	Jing Liu et al.	Guang Chen et al.	Dawei Wang et al.	Yanli Liu et al.	Jinjin Zhang et al.	Jiatao Lu et al.	Qilin Li et al.	Yichun Cheng et al.	Luwen Wang et al.
Period of study	2019.12.06 - 2020.1.2	2020.1.1-1.20	2019.12.10-2020.1.4	2020.01.05-01.24	2019.12.19-2020.1.27	2020.1.1-1.28	2020.1.2-2.1	2020.1.16-2.3	2020.1.21-2.5	2020.2.3-2.7	2020.1.28-2.11	2020.1.14-2.13
Location	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan	Wuhan
N	41	99	425	40	21	138	109	140	75	52	710	116
Case fatality rate, n (%)	6 (15)	11 (11)	NA	2 (5.0)	4 (19.0)	6/ (4.3)	31 (28.4)	NA	1/ (1.3)	NA	89 (12.5)	7 (6.0)
Severe cases, n (%)	NA	NA	NA	13 (32.5)	11 (52.4)	NA	NA	58 (41.4)	15/72 (20.8)	NA	252 (35.5)	46 (39.7)
Age,y, mean (sd)/median (IQR)	49 (5.2)	55.5 (13.1)	59 (12.3)	48.7 (13.9)	56.3 (14.3)	56 (11.7)	55 (43-66)	57 (25-87)	62 (48-71)	57 (49-69)	63 (51-71)	54 (38-69)
Male, n (%)	30 (73)	67 (68)	238 (56)	15 (37.5)	17 (81.0)	75/ (54.3)	59 (54.1)	71 (50.7)	37 (49.3)	26 (50.0)	374 (52.7)	67 (57.8)
Current smoking, n (%)	3(7)	NA	NA	NA	NA	NA	NA	2 (1.4)	NA	NA	NA	NA
Healthcare worker, n (%)	NA	NA	15 (3.5)	NA	NA	40 (29.0)	NA	3 (2.1)	NA	NA	NA	NA
Any comorbidity, n (%)	13 (32)	50 (51)	NA	14 (35.0)	7 (33.3)	64 (46.7)	NA	90 (64.3)	NA	NA	NA	51 (43.9)
Specific comorbidity, n (%)												
Hypertension	6 (14.6)	0	NA	6 (15.0)	5 (23.8)	43 (31.2)	37 (33.9)	42 (30.0)	20/46 (43.5)	NA	NA	43 (37.1)
Diabetes	8 (19.5)	12 (12.1)	NA	6 (15.0)	3 (14.3)	14 (10.1)	12 (11.0)	17 (12.1)	3/46 (6.5)	NA	NA	18 (15.5)
Cardiovascular diseases	6 (14.6)	40 (40.4)	NA	0	0	20 (14.5)	7 (6.4)	12 (8.6)	4/46 (8.7)	NA	NA	0
Cerebrovascular diseases	0	NA	0	0	0	7 (5.1)	6 (5.5)	3 (2.1)	2/46 (4.3)	NA	NA	7 (6.0)
COPD	1 (2.4)	1 (1.0)	NA	0	0	4 (2.9)	4 (3.7)	2 (1.4)	0/46 (0)	NA	NA	0
Cancer	1 (2.4)	0	NA	4 (10.0)	0	10 (7.2)	0	0	0	NA	NA	12 (10.3)
Chronic renal diseases	0	0	NA	0	0	4 (2.9)	10 (9.2)	2 (1.4)	0	NA	NA	5 (4.3)
Chronic liver disease	1 (2.4)	0	NA	0	0	4 (2.9)	0	8 (5.7)	5/46 (10.9)	NA	NA	0
Digestive system diseases	0	11 (11.1)	NA	0	0	0	0	7 (5.0)	0	NA	NA	0
Tuberculosis	0	0	NA	0	0	0	0	2 (1.4)	0	NA	NA	0
Abnormal lipid metabolism	0	0	NA	0	0	0	0	7 (5.0)	0	NA	NA	0
Cholelithiasis	0	0	NA	0	0	0	0	6 (4.3)	0	NA	NA	0
Thyroid disease	0	0	NA	2 (5.0)	0	0	0	0	0	NA	NA	0
HIV infection	0	0	NA	0	0	2 (1.4)	0	0	0	NA	NA	0
Symptom, n (%)												
Fever	40 (98)	82 (83)	NA	36 (90.0)	20/20 (100)	136 (98.6)	90 (82.6)	110/120 (91.7)	50/68 (73.5)	31/52 (59.6)	216/664 (32.5)	NA
Fatigue	18 (44)	11 (11)	NA	22 (55.0)	17/20 (85.0)	96(69.6)	62 (56.9)	90/120 (75.0)	29/68 (42.6)	1/52 (1.9)	NA	NA
Myalgia			NA	15 (37.5)	8/20 (40.0)	48 (34.8)			2/68(2.9)	NA	NA	NA
Headache	3/38 (8)	8 (8)	NA	8/40 (20.0)	2/20 (10.0)	9(6.5)	0	0	6/68 (8.8)	NA	NA	NA
Chill	0	0	NA	15 (37.5)	0	0	0	0	0	NA	NA	NA
Confusion/Dizziness	0	9 (9)	NA	7 (17.5)	0	13 (9.4)	0	0	0	NA	NA	NA
Coma	0	0	NA	0	1/21 (4.8)	0	0	0	0	NA	NA	NA
Dyspnea	22/40 (55)	0	NA	1 (2.5)	11/21 (52.4)	43 (31.2)	0	44/120 (36.7)	0	NA	NA	NA
Mild shortness of breath	0	31 (31)	NA	17 (42.5)	11/20 (55.0)	0	0	0	5/68 (7.4)	NA	NA	NA
Cough	31 (76)	81 (82)	NA	33 (82.5)	16/20 (80.0)	82 (59.4)	67 (61.5)	90/120 (75.0)	44/68 (64.7)	NA	NA	NA
Haemoptysis	2/39 (5)	0	NA	0	0	0	0	0	0	NA	NA	NA
Sputum production /Expectoration	11/39 (28)	0	NA	21 (52.5)	5/20 (25.0)	37 (26.8)	0	0	0	NA	NA	NA
Sore throat/Pharyngalgia	0	5 (5)	NA	5 (12.5)	0	24(17.4)	0	0	3/68 (4.4)	NA	NA	NA
Nasal congestion/Rhinorrhoea	0	4(4)	NA	1 (2.5)	0	0	0	0	1/68 (1.5)	NA	NA	NA
Chest pain	0	2 (2)	NA	1 (2.5)	0	0	7 (6.4)	0	0/68 (0)	NA	NA	NA
Abdominal pain	0	0	NA	1 (2.5)	0	3 (2.2)	0	8/139 (5.8)	0	NA	NA	NA

Anorexia	0	0	NA	0	0	55 (39.9)	0	17/139 (12.2)	0	NA	NA	NA
Nausea	0	1 (1)	NA	3 (7.5)	0	14 (10.1)	0	24/139 (17.3)	2/68 (2.9)	NA	NA	NA
Vomiting	0	0	NA	1 (2.5)	0	5 (3.6)	0	7/139 (5.0)	4/68 (5.9)	NA	NA	NA
Diarrhea	1/38 (3)	2 (2)	NA	3 (7.5)	4/20 (20.0)	14 (10.1)	12 (11.0)	118/139 (12.9)	5/68 (7.4)	NA	NA	NA
Laboratory findings, mean (sd)/median (IQR)												
WBC, × 10 <sup>9</sup> /L	6.2 (4.1-10.5)	7.5 (3.6)	NA	4.8 (2.6)	7.0 (3.6)	4.5 (3.3-6.2)	5.2 (4.0-7.0)	4.7 (3.7-6.7)	4.9 (3.6-6.8)	5.84 (3.75-7.93)	7.5 (7.5)	NA
N, × 10 <sup>9</sup> /L	5.0(3.3-8.9)	5.0 (3.3-8.1)	NA	2.8 (1.6-4.3)	5.7 (3.8)	3.0 (2.0-4.9)	3.6 (2.8-5.6)	NA	3.7 (2.3-5.4)	3.98 (2.39-5.57)	0.9 (0.5)	NA
L, × 10 <sup>9</sup> /L	0.8 (0.6-1.1)	0.9 (0.5)	NA	0.9 (0.7-1.3)	0.9 (0.4)	0.8 (0.6-1.1)	0.9 (0.5-1.2)	0.8 (0.6-1.1)	0.9 (0.6-1.2)	1.38 (0.66-2.09)	NA	NA
M, × 10 <sup>9</sup> /L	NA	NA	NA	0.3 (0.2-0.5)	NA	0.4 (0.3-0.5)	NA	NA	NA	0.43 (0.21-0.64)	NA	NA
CRP, mg/L	NA	51.4 (41.8)	NA	38.1 (4.7-65.2)	NA	NA	31 (11-54)	34.2 (12.5-67.4)	32.6 (11.6-39.0)	23.6 (-6.9-54.1)	NA	NA
Hb, g/L	126.0 (118.0-140.0)	129.8(14.8)	NA	126.4 (13.4)	137.0 (17.4)	NA	NA	NA	NA	140.8 (125.1-156.5)	128 (18)	NA
PLT, × 10 <sup>9</sup> /L	164.5(131.5-263.0)	213.5(79.1)	NA	183.1 (69.0)	162.7 (45.0)	163 (123-191)	NA	NA	NA	237.5 (135.2-335.9)	212 (94)	NA
PT, s	11.1 (10.1-12.4)	11.3(1.9)	NA	13.2 (0.6)	13.8 (1.0)	13.0 (12.3-13.7)	NA	NA	14.2 (13.4-15.6)	NA	NA	NA
Potassium, mmol/L	4.2(3.8-4.8)	NA	NA	3.8 (0.5)	NA	NA	NA	NA	NA	NA	4.2 (0.8)	NA
Sodium, mmol/L	139.0 (137.0-140.0)	NA	NA	145.9 (43.4)	NA	NA	NA	NA	NA	NA	139 (5)	NA
Scr, µmol/L	74.2(57.5-85.7)	75.6 (25.0)	NA	67.3 (19.7)	82.4 (30.3)	72 (60-87)	62 (55-82)	NA	67.0 (55.0-83.0)	NA	83 (84)	NA
CK, U/L	132.5 (62.0-219.0)	85.0 (51.0-184.0)	NA	59.5 (45.0-88.8)	153.7 (123.1)	92 (56-130)	91 (52-178)	72.5 (52.2-115)	NA	NA	165 (232)	NA
ALT, U/L	32.0(21.0-50.0)	39.0(22.0-53.0)	NA	22.5 (16.8-31.2)	30.0 (16.5)	24 (16-40)	23 (15-36)	NA	23.0 (17.0-35.0)	NA	36 (41)	NA
Albumin, g/L	31.4 (28.9-36.0)	31.6 (4.0)	NA	NA	34.4 (5.7)	NA	NA	NA	33.0 (30.3-37.3)	NA	NA	NA
APTT, s	27(24.2-34.1)	27.3 (10.2)	NA	39.5 (4.5)	40.0 (6.5)	31.4 (29.4-33.5)	NA	NA	NA	NA	NA	NA
D-dimer, mg/L	0.5 (0.3-1.3)	0.9 (0.5-2.8)	NA	0.6 (0.3-0.9)	4.0 (7.0)	203 (121-403)	570 (300-1178)	5.2 (0.1-0.5)	0.4 (0.1-1.2)	NA	NA	NA
AST, U/L	34.0(26.0-48.0)	34.0 (26.0-48.0)	NA	34.1 (17.7)	38.2 (24.6)	31 (24-51)	NA	NA	NA	NA	43 (50)	NA
TBil, mmol/L	11.7 (9.5-13.9)	15.1 (7.3)	NA	10.3 (5.0)	9.8 (5.6)	9.8 (8.4-14.1)	9.0 (6.5-13.4)	NA	9.2 (7.1-11.3)	NA	12 (23)	NA
LDH, U/L	286.0(242.0-408.0)	336.0 (260.0-447.0)	NA	303.9 (168.8)	408.1 (231.0)	261 (182-403)	238 (185-341)	NA	NA	NA	378 (195)	NA
cTnI, pg/mL	3.4 (1.1-9.1)	NA	NA	NA	NA	6.4 (2.8-18.5)	NA	NA	NA	NA	NA	NA
PCT, ng/mL	0.1 (0.1-0.1)	0.5 (1.1)	NA	NA	0.3 (0.5)	NA	0.09 (0.06-0.20)	0.07 (0.04-0.1)	NA	NA	NA	NA
BUN, mmol/L	NA	5.9 (2.6)	NA	3.2 (2.5-4.3)	6.1 (3.3)	4.4 (3.5-5.8)	4.3 (3.3-6.5)	NA	NA	NA	6.0 (5.0)	NA
Mb, ng/mL	NA	49.5 (33.2-99.8)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
IL-6, pg/mL	NA	7.9(6.1-10.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ESR, mm/h	NA	49.9 (23.4)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
SF, ng/mL	NA	808.7 (490.7)	NA	596.5 (308.6-1087.6)	1284.8 (934)	NA	NA	NA	NA	NA	NA	NA
Eosinophils, × 10 <sup>9</sup> /L	NA	NA	NA	NA	NA	NA	NA	0.01 (0.0-0.05)	NA	0.05 (-0.04-0.14)	NA	NA
CKMB, U/L	NA	NA	NA	NA	NA	14 (10-18)	9.0 (6.1-14.8)	NA	NA	NA	NA	NA
Fibrinogen, g/L	NA	NA	NA	5.1 (1.6)	NA	NA	3.1 (2.7-3.6)	NA	NA	NA	NA	NA
eGFR, ml/min/1.73m <sup>2</sup>	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	86 (24)	NA
Radiologic findings, n/N (%)												
Bilateral lung involvement	40 (98)	NA	NA	NA	17/21 (81.0)	NA	100/109 (91.7)	121/135 (89.6)	42/44 (95.5)	NA	NA	NA
Timeline of illness, d, mean (sd)/median (IQR)												
Days from illness onset to admission time	7 (4-8)	NA	NA	NA	6.4	7 (4-8)	7 (5-9)	8 (6-11)	6 (4.8)	NA	10 (7-13)	NA


**eTable 2. Raw data of clinical characteristics and laboratory results from included studies outside Wuhan (including the two nationwide studies).**

Study/year	Xiaowei Xu et al.	De Chang et al.	Jingyuan Liu et al.	Zhichao Feng et al.	Lei Liu et al.	Qingxian Cai et al.	Jinwei Ai et al.	Jingwen Ai et al.	Jie Li et al.	Hongzhou Lu et al.	Yang yang et al.	Weijie Guan et al.
Period of study	2020.1.10-1.26	2020.1.16-1.29	2020.1.13-1.31	2020.1.17-2.1	2020.1.20-2.3	2020.1.11-2.6	2019.12-2020.2.9	2020.1.22-2.9	2020.1.22-2.10	2020.1.20-2.19	2019.12-2020.1.26	2019.12-2020.1.29
Location	Zhejiang	Beijing	Beijing	Hunan	Chongqing	Shenzhen	Xiangyang, Hubei	Shanghai	Dazhou, Sichuan	Shanghai	Nationwide	Nationwide
N	62	13	61	141	51	298	102	20	17	265	4021	1099
Case fatality rate, n (%)	0 (0)	0 (0)	0 (0)	NA	1 (2.0)	0 (0)	3 (2.9)	NA	0 (0)	1 (0.4)	58 (1.4)	15 (1.4)
Severe cases, n (%)	NA	NA	3 (4.9)	15 (10.6)	7 (13.7)	58 (19.4)	NA	3 (15.0)	NA	22 (8.3)	935 (25.5)	173 (15.7)
Age,y, mean (sd)/median (IQR)	41 (32-52)	34 (34-38)	40 (14.2)	44 (34-55)	45 (34-51)	47 (33-61)	50.38 (16.86)	37 (33.75-50.5)	45.1 (12.8)	NA	48 (16)	47 (3.8)
Male, n (%)	36 (58.1)	10 (77)	31 (50.8)	72 (51.1)	32 (62.7)	149 (50.0)	52 (51.0)	10 (50.0)	9 (52.9)	NA	2213 (55.04)	649 (59.1)
Current smoking, n (%)	NA	NA	4 (6.6)	7 (5.0)	NA	NA	NA	NA	3 (17.6)	NA	NA	137/1085(12.6)
Healthcare worker, n (%)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	247 (6.14)	NA
Any comorbidity, n (%)	20 (32.3)	NA	NA	33 (23.4)	NA	NA	39 (38.2)	NA	3 (17.6)	NA	NA	255 (23.2)
Specific comorbidity, n (%)												
Hypertension	5 (8.1)	NA	12 (19.7)	21 (14.9)	4 (7.8)	38 (12.8)	NA	NA	1 (5.9)	52 (19.6)	NA	164 (14.9)
Diabetes	1 (1.6)	NA	5 (8.2)	8 (5.7)	4 (7.8)	19 (6.4)	NA	NA	NA	21 (7.9)	NA	81 (7.4)
Cardiovascular diseases	NA	NA	1 (1.6)	3 (2.1)	NA	11 (3.7)	NA	NA	NA	14 (5.3)	NA	27 (2.5)
Cerebrovascular diseases	1 (1.6)	NA	NA	1 (0.7)	NA	NA	NA	NA	NA	2 (0.08)	NA	15 (1.4)
COPD	1 (1.6)	NA	5 (8.2)	4 (2.8)	NA	NA	NA	NA	NA	4 (1.5)	NA	12 (1.1)
Cancer	NA	NA	NA	NA	NA	4 (1.4)	NA	NA	NA	6 (2.3)	NA	10 (0.9)
Chronic renal diseases	1 (1.6)	NA	NA	NA	NA	NA	NA	NA	NA	5 (1.9)	NA	8 (0.7)
Sinusitis	NA	NA	NA	NA	NA	NA	NA	NA	1 (5.9)	NA	NA	NA
Chronic liver disease	7 (11.3)	NA	NA	NA	NA	8 (2.7)	NA	NA	1 (5.9)	1 (0.4)	NA	NA
Chronic pharyngitis	NA	NA	NA	NA	NA	NA	NA	NA	1 (5.9)	NA	NA	NA
Hepatitis B infection	NA	NA	NA	4 (2.8)	1 (2.0)	NA	NA	NA	NA	NA	NA	23 (2.1)
Abnormal lipid metabolism	NA	NA	2 (3.3)	NA	NA	NA	NA	NA	NA	4 (1.5)	NA	NA
Immune system diseases	NA	NA	NA	NA	NA	NA	NA	NA	NA	2 (0.8)	NA	2 (0.2)
Symptom, n (%)												
Fever	48 (77.4)	12 (92.3)	60 (98.4)	105 (74.5)	43 (84.3)	192 (64.4)	86 (84.3)	16 (80.0)	12 (70.6)	220 (90.9)	NA	473 (43.1) 966 (87.9)
Fatigue		0	35 (57.4)	29 (20.6)	22 (43.1)	6 (2.0)	28 (27.5)	2 (10.0)	8 (47.1)	67 (25.3)	NA	419 (38.1)
Myalgia	32 (51.6)	3 (23.1)	0	0	6 (11.8)	0	3 (2.9)	0	4 (23.5)	23 (8.7)	NA	163 (14.8)
Headache	21 (33.9)	3 (23.1)	21 (34.4)	5 (3.5)	5 (9.8)	4 (1.3)	0	3 (15.0)	0	26 (9.8)	NA	150 (13.6)
Chill	0	0	12 (19.7)	0	0	0	12 (11.8)	0	0	0	NA	125 (11.4)
Confusion/Dizziness	0	0	0	0	7 (13.7)	0	4 (3.9)	0	2 (11.8)	0	NA	0
Dyspnea	0	0	3 (4.9)	0	11 (21.6)	0	0	0	0	5 (1.9)	NA	0
Mild shortness of breath	0	0	7 (11.5)	0	0	0	24 (23.5)	0	0	12 (4.5)	NA	204 (18.6)
Cough	50 (80.6)	6 (46.2)	39 (63.9)	74 (52.5)	38 (74.5)	54 (18.1)	58 (56.9)	11 (55.0)	13 (76.5)	131 (49.4)	NA	744 (67.7)
Haemoptysis	2 (3.2)	0	0	0	0	0	0	0	0	0	NA	10 (0.9)

Sputum production/ Expectoration	35 (56.5)	2 (15.4)	27 (44.3)	16 (11.3)	16 (31.4)	0	13 (12.7)	0	3(17.6)	61 (23.0)	NA	367 (33.4)
Sore throat/Pharyngalgia	0	0	10 (16.4)	0	2 (3.9)	3 (1.0)	6 (5.9)	0	0	12 (4.5)	NA	153 (13.9)
Nasal congestion/ Rhinorrhoea	0	8 (61.5)	0	0	3 (5.9)	2 (0.1)	0	0	2(11.8)	16 (6.0)	NA	53 (4.8)
Sneezing	0	0	0	0	0	0	0	0	0	0	NA	0
Throat congestion	0	0	0	0	0	0	0	0	0	0	NA	19 (1.7)
Tonsil swelling	0	0	0	0	0	0	0	0	0	0	NA	23 (2.1)
Respiratory failure	0	0	0	0	0	0	9 (8.8)	0	0	0	NA	0
Chest pain	0	0	1 (1.6)	0	0	0	3/102 (2.9)	0	0	6 (2.3)	NA	0
Palpitation	0	0	0	0	0	0	2 (2.0)	0	0	0	NA	0
Abdominal pain	0	0	0	0	0	0	3 (2.9)	0	0	0	NA	0
Anorexia	0	0	8 (13.1)	5 (3.5)	0	0	11 (10.8)	0	0	31 (11.7)	NA	0
Nausea	0	0	5 (8.2)	0	3 (5.9)	0	9 (8.8)	1 (5.0)	0	6 (2.3)	NA	55 (5.0)
Vomiting	0	0	0	0	3 (5.9)	0	2 (2.0)	0	0	0	NA	0
Diarrhea	3 (4.8)	1 (7.7)	6 (9.8)	6 (4.3)	4 (7.8)	6 (2.0)	15 (14.3)	3 (15.0)	2(11.8)	17 (6.4)	NA	41 (3.7)
Laboratory findings, mean (sd)/median (IQR)												
WBC, × 10 <sup>9</sup> /L	4.7 (3.5-5.8)	5.83 (2.32)	4.3 (3.5-5.1)	4.6 (3.4-6.3)	5.4 (4.1-7.6)	4.59 (3.64-5.63)	4.84 (1.62)	4.21 (4.03-6.70)	6.2(2.5)	4.6 (3.8-5.9)	NA	4.7 (3.5-6.0)
N, × 10 <sup>9</sup> /L	2.9 (2.0-3.7)	3.67 (1.71)	2.5 (2.1-3.5)	3.4 (2.3-4.3)	3.7 (2.5-6.0)	2.57 (1.93-3.49)	3.21 (1.43)	2.88 (2.25-4.63)	4.6(2.8)	1.1 (0.8-1.5)	NA	NA
L, × 10 <sup>9</sup> /L	1 (0.8-1.5)	1.58 (0.653)	1.0 (0.8-1.4)	1.1 (0.7-1.6)	1.22 (0.91-1.74)	1.18 (0.73)	1.21 (0.91-1.46)	1.1(0.5)	2.9 (2.3-3.9)	NA	NA	1.0 (0.7-1.3)
M, × 10 <sup>9</sup> /L	NA	0.527 (0.208)	0.3 (0.2-0.4)	NA	NA	NA	0.41 (0.19)	NA	0.4(0.2)	NA	NA	NA
NLR	NA	NA	2.6 (1.6-3.5)	3.4 (2.1-4.2)	NA	NA	NA	NA	NA	NA	NA	NA
CRP, mg/L	NA	14.7 (10.2)	12.0 (3.7-27.8)	21.7 (9.4-33.5)	10.5 (2.7-51.2)	20.91 (6.61-47.13)	28.16 (26.72)	9.68 (1.63-25.83)	32.1(34.2)	9.8 (2.5-27.4)	NA	NA
Hb, g/L	137.0 (128.8-152.3)	147 (12.1)	138.0 (127.0-150.5)	NA	136 (123-152)	NA	NA	145 (131.25-158)	140.5(13.1)	136.1 (18.01)	NA	134.0 (119.0-148.0)
PLT, × 10 <sup>9</sup> /L	176.0 (135.8-215.5)	199 (72.5)	164.0 (135.0-219.5)	188.5 (134.8-240.0)	189 (134-235)	NA	NA	199 (146-248.25)	227.1(111.6)	176 (141-219)	NA	168.0 (132.0-207.0)
PT, s	NA	NA	12.0 (11.1-13.1)	NA	NA	NA	NA	NA	11.8(0.9)	13.3 (13.00-13.)	NA	NA
Potassium, mmol/L	3.7 (3.5-3.9)	NA	3.8 (3.5-4.1)	NA	NA	NA	NA	NA	NA	3.80 (3.60-4.00)	NA	3.8 (3.5-4.2)
Sodium, mmol/L	139 (127-141)	NA	139.0 (137.0-140.0)	NA	NA	NA	NA	NA	NA	139 (137-141)	NA	138.2 (136.1-140.3)
Scr, µmol/L	72.0 (61.0-84.0)	NA	60.0 (47.0-69.5)	73.3 (65.4-75.5)	67 (60-79)	102 (72-122)	NA	NA	65.8(14.1)	63.6 (52.4-76.1)	NA	NA
CK, U/L	69.0 (40.5-101.0)	NA	93.0 (57.0-137.0)	NA	52 (38-79)	283 (105-407.5)	139.32 (121.66)	NA	114.9(91.8)	83 (56-133)	NA	NA
ALT, U/L	22 (14-34)	NA	19.0 (14.0-33.5)	NA	18 (14-30)	48 (24.5-59.5)	27.77 (21.13)	21.50 (15-31.25)	NA	23.0 (15.0-33.0)	NA	NA
Albumin, g/L	NA	NA	44.0 (40.5-47.0)	38 (32.7-39.2)	40 (36-43)	NA	NA	43 (40.5-46.95)	NA	40.8 (37.8-43.0)	NA	NA
APTT, s	NA	NA	NA	NA	NA	NA	NA	NA	31.1(2.6)	39.5 (36.3-42.6)	NA	NA
D-dimer, mg/L	0.2 (0.2-0.5)	NA	NA	NA	0.28 (0.19-0.51)	0.39 (0.27-0.63)	NA	NA	217.4(150.0)	0.42 (0.29-0.80)	NA	NA
ASL, U/L	26 (20-32)	NA	NA	NA	21 (16-30)	48 (30-65)	30.59 (15.03)	23 (18.5-27)	NA	24.0 (19.0-33.0)	NA	NA
TBil, mmol/L	NA	NA	NA	NA	NA	14 (10-22)	NA	6.70 (6.15-7.75)	17.7(13.5)	7.9 (6.5-10.5)	NA	NA
LDH, U/L	205.0 (184.0-260.0)	NA	NA	NA	231 (188-276)	412.5 (317.8-687.3)	245.38 (14.35)	NA	316.2(115.9)	232 (195-293)	NA	NA
cTnI, pg/mL	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.02 (0.01-0.04)	NA	NA
PCT, ng/mL	0.04 (0.03-0.06)	NA	NA	NA	0.04 (0.03-0.07)	0.05 (0.03-0.08)	NA	NA	0.064(0.059)	0.03 (0.02-0.06)	NA	NA

BUN, mmol/L	NA	NA	4.3 (3.5-5.6)	NA	4.1 (3.3-5.7)	8 (6-10)	NA	NA	NA	NA	NA	NA
Mb, ng/mL	NA	NA	NA	NA	NA	127.5 (67.75-216.25)	39.61 (30.87)	NA	NA	6.7 (3.1-15.3)	NA	NA
ESR, mm/h	NA	NA	NA	NA	NA	30 (15-50)	33.30 (23.39)	NA	NA	50.5 (29.0-90.0)	NA	NA
SF, ng/mL	NA	NA	NA	NA	NA	NA	269.89 (124.88)	NA	NA	NA	NA	NA
Eosinophils, ×10 <sup>9</sup> /L	NA	0.045 (0.072)	NA	NA	NA	NA	NA	NA	0.02(0.03)	NA	NA	NA
Basophils, ×10 <sup>9</sup> /L	NA	0.008 (0.006)	NA	NA	NA	NA	NA	NA	0.0007(0.003)	NA	NA	NA
CKMB, U/L	NA	NA	NA	NA	NA	1.5 (1.0-4.25)	13.94 (10.25)	NA	15.2(3.7)	NA	NA	NA
Fibrinogen, g/L	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NT-proBNP, pg/ml	NA	NA	NA	NA	NA	NA	NA	NA	NA	34.6 (23.0-67.6)	NA	NA
eGFR, ml/min/1.73m <sup>2</sup>	NA	NA	NA	NA	NA	NA	NA	NA	NA	110 (96-127)	NA	NA
Lactic acid, mmol/L	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.74 (2.33-3.21)	NA	NA
Radiologic findings, n/N (%)												
Bilateral lung involvement	52 (83.9)	NA	48 (78.7)	123 (87.2)	NA	NA	NA	NA	NA	205 (77.4)	NA	NA
Timeline of illness, d, mean (sd)/median (IQR)												
Days from illness onset to admission time	2 (1-4)	NA	5 (0-23)	4 (2-7)	6 (3-8)	5 (2-7)	NA	NA	NA	5.5 (5.1-5.9)	5 (2-9)	NA
Incubation period, days	4 (3-5)	NA	NA	NA	NA	NA	8.09 (4.99)	NA	NA	6.4 (5.3-7.6)	NA	NA

**eFigure 1. Flow chart of studies selection.**




N, the number of COVID-19 confirmed patients; ICU, intensive care unit.


<sup>a</sup> EndNote software (Clarivate Analytics) was used to remove duplicates.

**eFigure 2. Forest plot of CSR and CFR.**

**CSR**



**CFR**



**eFigure 3. Meta-regression data for CSR and CFR using comprehensive meta-analysis software.**

Multivariate meta-regression for location and observation time on logit CSR

Set	Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Location	Intercept	0.7723	0.9205	-1.0319	2.5765	0.84	0.4015
	Location: 2 Outside Wuhan in	-1.3703	0.3249	-2.0071	-0.7334	-4.22	0.0000
	Location: 3 Nationwide	-1.2806	0.5192	-2.2982	-0.2630	-2.47	0.0136
	Date	-0.0270	0.0180	-0.0623	0.0083	-1.50	0.1339

$Q=22.57, df=2, p=0.0000$

**Statistics for Model 1**

**Test of the model:** Simultaneous test that all coefficients (excluding intercept) are zero  
 $Q = 26.26, df = 3, p = 0.0000$

**Goodness of fit:** Test that unexplained variance is zero  
 $Tau^2 = 0.2434, Tau = 0.4933, I^2 = 90.71\%, Q = 129.23, df = 12, p = 0.0000$

Univariate meta-regression for onset-to-admission time on logit CSR

Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Intercept	-2.5759	1.0216	-4.5783	-0.5735	-2.52	0.0117
	0.2302	0.1626	-0.0884	0.5488	1.42	0.1568

**Statistics for Model 1**

**Test of the model:** Simultaneous test that all coefficients (excluding intercept) are zero  
 $Q = 2.00, df = 1, p = 0.1568$

**Goodness of fit:** Test that unexplained variance is zero  
 $Tau^2 = 0.8132, Tau = 0.9018, I^2 = 96.61\%, Q = 235.83, df = 8, p = 0.0000$

Multivariate meta-regression for location and observation time on logit CFR

Set	Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Location	Intercept	-1.5253	0.8924	-3.2743	0.2237	-1.71	0.0874
	Location: 2 Outside Wuhan in	-1.8151	0.6863	-3.1602	-0.4700	-2.64	0.0082
	Location: 3 Nationwide	-2.2079	0.6117	-3.4068	-1.0090	-3.61	0.0003
	Date	-0.0162	0.0196	-0.0546	0.0222	-0.83	0.4081

$Q=18.39, df=2, p=0.0001$

**Statistics for Model 1**

**Test of the model:** Simultaneous test that all coefficients (excluding intercept) are zero  
 $Q = 18.39, df = 3, p = 0.0004$

**Goodness of fit:** Test that unexplained variance is zero  
 $Tau^2 = 0.4672, Tau = 0.6835, I^2 = 77.59\%, Q = 49.09, df = 11, p = 0.0000$

Univariate meta-regression for onset-to-admission time on logit CFR

Covariate	Coefficient	Standard Error	95% Lower	95% Upper	Z-value	2-sided P-value
Intercept	-5.9623	1.4962	-8.8947	-3.0299	-3.99	0.0001
	0.4868	0.2391	0.0181	0.9555	2.04	0.0418

**Statistics for Model 1**


**Test of the model:** Simultaneous test that all coefficients (excluding intercept) are zero  
 $Q = 4.14, df = 1, p = 0.0418$

**Goodness of fit:** Test that unexplained variance is zero  
 $Tau^2 = 1.6701, Tau = 1.2923, I^2 = 92.54\%, Q = 133.96, df = 10, p = 0.0000$


**eFigure 4. Forest plots of clinical and baseline characteristics.**

**eFigure 4. 1. Forest plot of age.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 2. Forest plot of onset-to-admission time.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



## D. Severe cases




### E. Non-severe cases




**eFigure 4. 3. Forest plot of WBC, white blood cell count.**


A. Overall




## B. Wuhan




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 4. Forest plot of N, neutrophil count.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



## D. Severe cases




## E. Non-severe cases




**eFigure 4. 5. Forest plot of L, lymphocyte count.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### F. Non-severe cases




**eFigure 4. 6. Forest plot of M, monocyte count.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




#### F. Non-severe cases




**eFigure 4. 7. Forest plot of Hb, hemoglobin.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### F. Non-severe cases




**eFigure 4. 8. Forest plot of PLT, platelet count.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




## F. Non-severe cases




**eFigure 4. 9. Forest plot of CRP, C-reactive protein.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 10. Forest plot of PCT, procalcitonin.**


A. Overall




B. Wuhan



### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 11. Forest plot of LDH, lactate dehydrogenase.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 12. Forest plot of CK, creatine kinase.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 13. Forest plot of Mb, myoglobin.**

A. Overall




**eFigure 4. 14. Forest plot of ALT, alanine aminotransferase.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 15. Forest plot of AST, aspartate aminotransferase.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 16. Forest plot of Albumin.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




## E. Non-severe cases




**eFigure 4. 17. Forest plot of Tbil, total bilirubin.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 18. Forest plot of Scr, serum creatinine.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 19. Forest plot of BUN, blood urea nitrogen.**


A. Overall




## B. Wuhan



## C. Severe cases




#### D. Non-severe cases




**eFigure 4. 20. Forest plot of eGFR.**


A. Overall



## B. Severe cases




## C. Non-severe cases




**eFigure 4. 21. Forest plot of Potassium.**


**A. Overall**




**B. Wuhan**




### C. Outside Wuhan



### D. Severe cases




### E. Non-severe cases




**eFigure 4. 20. Forest plot of PT, prothrombin time.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 22. Forest plot of Sodium**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




## E. Non-severe cases




**eFigure 4. 23. Forest plot of APTT, activated partial thromboplastin time.**


A. Overall




## B. Wuhan




## C. Outside Wuhan



#### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 24. Forest plot of D-dimer.**


A. Overall




B. Wuhan




### C. Outside Wuhan



### D. Severe cases




#### E. Non-severe cases




**eFigure 4. 25. Forest plot of SF, serum ferritin.**


A. Overall




## B. Wuhan



## C. Severe cases




#### D. Non-severe cases




**eFigure 5. Estimated risk of medical conditions for severity of COVID-19 (A. Mean Difference [MD] in age between severe and non-severe cases).**


**A Age**




**B Smoking**




**C CVD**




**E Hepatitis B infection**



**D Cancer**




**F Bilateral lung involvement**



## eFigure 6. Estimated risk of abnormal laboratory index for severity of COVID-19.


### A High CK




### B High CRP




### C High D-dimer



### D Lymphocytopenia



### E High LDH




### F Thrombocytopenia




A, high CK, CK > 200 U/L; B, high CRP, CRP > 10mg/L; C, high D-dimer, D-dimer > 0.5mg/L; D, lymphocytopenia, lymphocyte count < 1.1 × 10<sup>9</sup>/L; E, high LDH, LDH > 250U/L; F, thrombocytopenia, PLT count < 150 × 10<sup>9</sup>/L

**eFigure 7. MD in laboratory index between severe and non-severe cases of COVID-19.**


**A ALB**




**B ALT**




**C ESR**



**D Scr**




**E Sodium**




**eFigure 8. Forest plot showing result of sensitive analysis after excluding 1 study in turn.**

**A CSR**




**B CFR**




**eFigure 9. Funnel plot.**

A CSR



B CFR



Center line represents the summary effect estimate. Outer dotted lines display 95% CIs.  
Begger's test, Egger's test and Peter's test indicated no publication bias for both CSR and CFR  
A (Begger:  $P = 0.73$ ; Peter:  $P = 0.32$ );  
B (Begger:  $P = 0.16$ ; Peter:  $P = 0.10$ ).

## eReferences.

1. C H, Y W, X L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)* 2020.
2. JP M, GW W, AC L, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *American journal of respiratory and critical care medicine* 2019; **200**(7): e45-e67.